Apyrase homolog; Putative MAPK-activating protein P; M09; Putative NF-kappa-B-activating protein 107

For Research Use Only. Not for use in diagnostic procedures.

E Coli

Greater than 90% as determined by SDS-PAGE. (lot specific)

Liquid containing glycerol

This protein contains an N-terminal tag and may also contain a C-terminal tag. Tag types are determined by various factors including tag-protein stability, please inquire for tag information.

Sterile filter available upon request.

Low endotoxin available upon request.

Store at -20 degree C, for extended storage, conserve at -20 degree C or -80 degree C.

Manufactured in an ISO 13485:2003 and EN ISO 13485:2012 Certified Laboratory.

Small volumes of SHAPY recombinant protein vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Calcium-dependent nucleotidase with a preference for UDP. The order of activity with different substrates is UDP > GDP > UTP > GTP. Has very low activity towards ADP and even lower activity towards ATP. Does not hydrolyze AMP and GMP. Involved in proteoglycan synthesis.

Epigenetics and Nuclear Signaling

(Note: Representative image, actual molecular weight may vary depending on Tag type and expression host)

39.4kD

calcium activated nucleotidase 1

soluble calcium-activated nucleotidase 1

Soluble calcium-activated nucleotidase 1

SHAPY; SCAN-1??[Similar Products]

CANT1_HUMAN

This protein encoded by this gene belongs to the apyrase family. It functions as a calcium-dependent nucleotidase with a preference for UDP. Mutations in this gene are associated with Desbuquois dysplasia with hand anomalies. Alternatively spliced transcript variants have been noted for this gene.[provided by RefSeq, Mar 2010]

CANT1: Calcium-dependent nucleotidase with a preference for UDP. The order of activity with different substrates is UDP > GDP > UTP > GTP. Has very low activity towards ADP and even lower activity towards ATP. Does not hydrolyze AMP and GMP. Involved in proteoglycan synthesis. Defects in CANT1 are the cause of Desbuquois dysplasia (DBQD). A chondrodysplasia characterized by severe prenatal and postnatal growth retardation (less than -5 SD), joint laxity, short extremities, progressive scoliosis, round face, midface hypoplasia, prominent bulging eyes. The main radiologic features are short long bones with metaphyseal splay, a 'Swedish key' appearance of the proximal femur (exaggerated trochanter), and advance carpal and tarsal bone age. Two forms of Desbuquois dysplasia are distinguished on the basis of the presence (type 1) or absence (type 2) of characteristic hand anomalies: an extra ossification center distal to the second metacarpal, delta phalanx, bifid distal thumb phalanx, and phalangeal dislocations. Belongs to the apyrase family. 2 isoforms of the human protein are produced by alternative splicing.

Protein type: EC 3.6.1.6; Membrane protein, integral; Endoplasmic reticulum; Nucleotide Metabolism - pyrimidine; Hydrolase; Nucleotide Metabolism - purine

Chromosomal Location of Human Ortholog: 17q25.3

Cellular Component: endoplasmic reticulum membrane; integral to membrane

Molecular Function: calcium ion binding; guanosine-diphosphatase activity; signal transducer activity; uridine-diphosphatase activity

Biological Process: positive regulation of I-kappaB kinase/NF-kappaB cascade; proteoglycan biosynthetic process; signal transduction

Disease: Desbuquois Dysplasia 1

Cloning, expression, and characterization of a soluble calcium-activated nucleotidase, a human enzyme belonging to a new family of extracellular nucleotidases.Smith T., Hicks-Berger C., Kim S., Kirley T.Arch. Biochem. Biophys. 406:105-115(2002) Large-scale identification and characterization of human genes that activate NF-kappaB and MAPK signaling pathways.Matsuda A., Suzuki Y., Honda G., Muramatsu S., Matsuzaki O., Nagano Y., Doi T., Shimotohno K., Harada T., Nishida E., Hayashi H., Sugano S.Oncogene 22:3307-3318(2003) Complete sequencing and characterization of 21,243 full-length human cDNAs.Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.Nat. Genet. 36:40-45(2004) Cloning, expression, and functional characterization of a Ca2+-dependent endoplasmic reticulum nucleoside diphosphatase.Failer B.U., Braun N., Zimmermann H.J. Biol. Chem. 277:36978-36986(2002) Site-directed mutagenesis of human soluble calcium-activated nucleotidase 1 (hSCAN-1) identification of residues essential for enzyme activity and the Ca(2+) -induced conformational change.Yang M., Kirley T.L.Biochemistry 43:9185-9194(2004) Mutation of CANT1 causes Desbuquois dysplasia.Faden M., Al-Zahrani F., Arafah D., Alkuraya F.S.Am. J. Med. Genet. A 152:1157-1160(2010) Further delineation of CANT1 phenotypic spectrum and demonstration of its role in proteoglycan synthesis.Nizon M., Huber C., De Leonardis F., Merrina R., Forlino A., Fradin M., Tuysuz B., Abu-Libdeh B.Y., Alanay Y., Albrecht B., Al-Gazali L., Basaran S.Y., Clayton-Smith J., Desir J., Gill H., Greally M.T., Koparir E., van Maarle M.C., Mackay S., Mortier G., Morton J., Sillence D., Vilain C., Young I., Zerres K., Le Merrer M., Munnich A., Le Goff C., Rossi A., Cormier-Daire V.Hum. Mutat. 33:1261-1266(2012) Structure and protein design of a human platelet function inhibitor.Dai J., Liu J., Deng Y., Smith T.M., Lu M.Cell 116:649-659(2004) Identification of CANT1 mutations in Desbuquois dysplasia.Huber C., Oules B., Bertoli M., Chami M., Fradin M., Alanay Y., Al-Gazali L.I., Ausems M.G., Bitoun P., Cavalcanti D.P., Krebs A., Le Merrer M., Mortier G., Shafeghati Y., Superti-Furga A., Robertson S.P., Le Goff C., Muda A.O., Paterlini-Brechot P., Munnich A., Cormier-Daire V.Am. J. Hum. Genet. 85:706-710(2009) Desbuquois dysplasia type I and fetal hydrops due to novel mutations in the CANT1 gene.Laccone F., Schoner K., Krabichler B., Kluge B., Schwerdtfeger R., Schulze B., Zschocke J., Rehder H.Eur. J. Hum. Genet. 19:1133-1137(2011) A founder mutation of CANT1 common in Korean and Japanese Desbuquois dysplasia.Dai J., Kim O.H., Cho T.J., Miyake N., Song H.R., Karasugi T., Sakazume S., Ikema M., Matsui Y., Nagai T., Matsumoto N., Ohashi H., Kamatani N., Nishimura G., Furuichi T., Takahashi A., Ikegawa S.J. Hum. Genet. 56:398-400(2011) CANT1 mutation is also responsible for Desbuquois dysplasia, type 2 and Kim variant.Furuichi T., Dai J., Cho T.J., Sakazume S., Ikema M., Matsui Y., Baynam G., Nagai T., Miyake N., Matsumoto N., Ohashi H., Unger S., Superti-Furga A., Kim O.H., Nishimura G., Ikegawa S.J. Med. Genet. 48:32-37(2011)

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.